Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Lisavanbulin (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 04 Jan 2019 According to a Basilea Pharmaceutica media release, this study could be completed by mid-2020 and is conducted in collaboration with the Adult Brain Tumor Consortium (ABTC), which is funded by the U.S. National Cancer Institute.
- 31 Aug 2018 Biomarkers information updated
- 11 May 2018 Planned End Date changed from 15 Jul 2021 to 15 Jul 2022.